Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike protein vaccine: a randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)

View ORCID ProfileFrancisco Hernández-Bernal, Maria C. Ricardo-Cobas, View ORCID ProfileYenima Martín-Bauta, View ORCID ProfileZadis Navarro-Rodríguez, View ORCID ProfileMarjoris Piñera-Martínez, Joel Quintana-Guerra, Karen Urrutia-Pérez, Klaudia Urrutia-Pérez, View ORCID ProfileCristina O. Chávez-Chong, View ORCID ProfileJorge L. Azor-Hernández, José L. Rodríguez-Reinoso, Leonardo Lobaina-Lambert, Elizabeth Colina-Ávila, Jacqueline Bizet-Almeida, Jeniffer Rodríguez-Nuviola, Sergio del Valle-Piñera, Mayara Ramírez-Domínguez, Elisangela Tablada-Ferreiro, Marel Alonso-Valdés, View ORCID ProfileGilda Lemos-Pérez, Gerardo E. Guillén-Nieto, Ariel Palenzuela-Díaz, View ORCID ProfileEnrique Noa-Romero, View ORCID ProfileMiladys Limonta-Fernández, Juan M. Fernández-Ávila, Nabil A. Ali-Mros, Lianne del Toro-Lahera, Rossana Remedios-Reyes, Marta Ayala-Ávila, View ORCID ProfileVerena L. Muzio-González, for the ABDALA Group of Investigators
doi: https://doi.org/10.1101/2021.11.30.21267047
Francisco Hernández-Bernal
1Center for Genetic Engineering and Biotechnology, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Francisco Hernández-Bernal
  • For correspondence: hernandez.bernal@cigb.edu.cu
Maria C. Ricardo-Cobas
2“Saturnino Lora” Hospital, Santiago de Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yenima Martín-Bauta
1Center for Genetic Engineering and Biotechnology, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yenima Martín-Bauta
Zadis Navarro-Rodríguez
2“Saturnino Lora” Hospital, Santiago de Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zadis Navarro-Rodríguez
Marjoris Piñera-Martínez
2“Saturnino Lora” Hospital, Santiago de Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marjoris Piñera-Martínez
Joel Quintana-Guerra
1Center for Genetic Engineering and Biotechnology, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Urrutia-Pérez
1Center for Genetic Engineering and Biotechnology, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klaudia Urrutia-Pérez
1Center for Genetic Engineering and Biotechnology, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristina O. Chávez-Chong
3Institute of Cybernetics, Mathematics and Physics, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cristina O. Chávez-Chong
Jorge L. Azor-Hernández
3Institute of Cybernetics, Mathematics and Physics, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jorge L. Azor-Hernández
José L. Rodríguez-Reinoso
1Center for Genetic Engineering and Biotechnology, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leonardo Lobaina-Lambert
2“Saturnino Lora” Hospital, Santiago de Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Colina-Ávila
2“Saturnino Lora” Hospital, Santiago de Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacqueline Bizet-Almeida
2“Saturnino Lora” Hospital, Santiago de Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeniffer Rodríguez-Nuviola
2“Saturnino Lora” Hospital, Santiago de Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergio del Valle-Piñera
2“Saturnino Lora” Hospital, Santiago de Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mayara Ramírez-Domínguez
2“Saturnino Lora” Hospital, Santiago de Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisangela Tablada-Ferreiro
2“Saturnino Lora” Hospital, Santiago de Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marel Alonso-Valdés
1Center for Genetic Engineering and Biotechnology, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gilda Lemos-Pérez
1Center for Genetic Engineering and Biotechnology, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gilda Lemos-Pérez
Gerardo E. Guillén-Nieto
1Center for Genetic Engineering and Biotechnology, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ariel Palenzuela-Díaz
4Immunoassay Center, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Enrique Noa-Romero
5Civilian Defense Scientific Research Center, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Enrique Noa-Romero
Miladys Limonta-Fernández
1Center for Genetic Engineering and Biotechnology, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Miladys Limonta-Fernández
Juan M. Fernández-Ávila
2“Saturnino Lora” Hospital, Santiago de Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nabil A. Ali-Mros
2“Saturnino Lora” Hospital, Santiago de Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lianne del Toro-Lahera
2“Saturnino Lora” Hospital, Santiago de Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rossana Remedios-Reyes
2“Saturnino Lora” Hospital, Santiago de Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marta Ayala-Ávila
1Center for Genetic Engineering and Biotechnology, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Verena L. Muzio-González
1Center for Genetic Engineering and Biotechnology, Havana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Verena L. Muzio-González
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Aim To evaluate the safety and immunogenicity of a SARS-CoV-2 recombinant spike protein vaccine (Abdala), administered intramuscularly in different strengths and vaccination schedules.

Method A phase 1-2, randomized, double-blind, placebo-controlled trial was done. Subjects were randomly distributed in 3 groups: placebo, 25 and 50µg RBD. The product was applied intramuscularly, 0.5 mL in the deltoid region. During the first phase, two immunization schedules were studied: short (0-14-28 days) and long (0-28-56 days). In phase 2, only the short scheme was evaluated. The main endpoints were: safety and proportion of subjects with seroconversion of anti-RBD IgG antibodies to SARS-CoV-2. Blood samples were collected in several points according to the corresponding vaccination schedule to determine the level of RBD-specific IgG antibodies (seroconversion rates and geometric mean of the titers), the percentage of inhibition of RBD-ACE-2 binding and levels of neutralizing antibodies.

Results The product was well tolerated. Severe adverse events were not reported. Adverse reactions were minimal, mostly mild and local (from the injection site), resolved in the first 24-48 hours without medication. In phase 1, at day 56 (28 days after the third dose of the short vaccination schedule, 0-14-28 days) seroconversion of anti-RBD IgG was seen in 95.2 % of the participants (20/21) for the 50μg group and 81 % of the participants (17/21) for the 25μg group, and none in the placebo group (0/22); whereas neutralizing antibodies to SARS-CoV-2 were seen in 80 % of the participants (8/10) for the 50μg group and 94.7% of the participants (18/19) for the 25μg group. For the long schedule, at day 70 (14 days after the third dose) seroconversion of anti-RBD IgG was seen in 100% of the participants (21/21) for the 50μg group and 94.7% of the participants (18/19) for the 25μg group, and none in the placebo group (0/22); whereas neutralizing antibodies to SARS-CoV-2 were seen in 95 % of the participants (19/20) for the 50μg group and 93.8% of the participants (15/16) for the 25μg group In phase 2, at day 56 seroconversion of anti-RBD IgG was seen in 89.2% of the participants (214/240) for the 50μg group, 77.7% of the participants (185/238) for the 25μg group, and 4.6% in the placebo group (11/239); whereas neutralizing antibodies to SARS-CoV-2 were seen in 97.3% of the participants (146/150) for the 50μg group and 95.1% of the participants (58/61) for the 25μg group.

Conclusion Abdala vaccine against SARS-CoV-2 was safe, well tolerated and induced humoral immune responses against SARS-CoV-2 among adults from 19 to 80 years of age.

Trial registration / Review protocol RPCEC00000346. Cuban Public Clinical Trial Registry (WHO accepted Primary Registry).

Available from: https://rpcec.sld.cu/en/trials/RPCEC00000346-En

Information about the ethical aspects and IRB approval The protocol was approved by the Ethic Committee of the participating hospital and by the Cuban Regulatory Authority (Center for State Control of Drugs, Medical Devices and Equipment).

Summary box COVID-19 is a serious global health problem. Vaccines are urgently needed to protect humanity. Multiple vaccine candidates are currently being evaluated. The article shows promising safety and immunogenicity results for a vaccine candidate, based on the recombinant RBD subunit of the spike protein.

Competing Interest Statement

Authors FHB, YMB, JQG, KUP, JLRR, MAV, MLF, GEGN, GLP, MAA, and VLMG, are employees of the Center for Genetic Engineering and Biotechnology, Havana Network, where Abdala vaccine active ingredient is produced and the formulation was developed. The remaining authors have no conflict of interests. No honoraria, consulting fees or payments for seminar presentations, speeches or appearances have been received by any of the authors. The study was financed by CIGB, Havana (products, reagents) and the Ministry of Public Health of Cuba (hospital facilities and general medical care of the participants).

Clinical Trial

RPCEC00000346. Cuban Public Clinical Trial Registry (WHO accepted Primary Registry).

Funding Statement

Public Health Ministry of Cuba

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee/IRB of Provincial Hospital "Saturnino Lora" in Santiago de Cuba, gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced are available at data base, clinic history, Cuban drug regulatory agency, ecc.

Data Availability

All data produced are available at data base, clinic history, Cuban drug regulatory agency, ecc.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted December 03, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike protein vaccine: a randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike protein vaccine: a randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)
Francisco Hernández-Bernal, Maria C. Ricardo-Cobas, Yenima Martín-Bauta, Zadis Navarro-Rodríguez, Marjoris Piñera-Martínez, Joel Quintana-Guerra, Karen Urrutia-Pérez, Klaudia Urrutia-Pérez, Cristina O. Chávez-Chong, Jorge L. Azor-Hernández, José L. Rodríguez-Reinoso, Leonardo Lobaina-Lambert, Elizabeth Colina-Ávila, Jacqueline Bizet-Almeida, Jeniffer Rodríguez-Nuviola, Sergio del Valle-Piñera, Mayara Ramírez-Domínguez, Elisangela Tablada-Ferreiro, Marel Alonso-Valdés, Gilda Lemos-Pérez, Gerardo E. Guillén-Nieto, Ariel Palenzuela-Díaz, Enrique Noa-Romero, Miladys Limonta-Fernández, Juan M. Fernández-Ávila, Nabil A. Ali-Mros, Lianne del Toro-Lahera, Rossana Remedios-Reyes, Marta Ayala-Ávila, Verena L. Muzio-González, for the ABDALA Group of Investigators
medRxiv 2021.11.30.21267047; doi: https://doi.org/10.1101/2021.11.30.21267047
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike protein vaccine: a randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)
Francisco Hernández-Bernal, Maria C. Ricardo-Cobas, Yenima Martín-Bauta, Zadis Navarro-Rodríguez, Marjoris Piñera-Martínez, Joel Quintana-Guerra, Karen Urrutia-Pérez, Klaudia Urrutia-Pérez, Cristina O. Chávez-Chong, Jorge L. Azor-Hernández, José L. Rodríguez-Reinoso, Leonardo Lobaina-Lambert, Elizabeth Colina-Ávila, Jacqueline Bizet-Almeida, Jeniffer Rodríguez-Nuviola, Sergio del Valle-Piñera, Mayara Ramírez-Domínguez, Elisangela Tablada-Ferreiro, Marel Alonso-Valdés, Gilda Lemos-Pérez, Gerardo E. Guillén-Nieto, Ariel Palenzuela-Díaz, Enrique Noa-Romero, Miladys Limonta-Fernández, Juan M. Fernández-Ávila, Nabil A. Ali-Mros, Lianne del Toro-Lahera, Rossana Remedios-Reyes, Marta Ayala-Ávila, Verena L. Muzio-González, for the ABDALA Group of Investigators
medRxiv 2021.11.30.21267047; doi: https://doi.org/10.1101/2021.11.30.21267047

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1099)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9781)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2317)
  • Geriatric Medicine (223)
  • Health Economics (462)
  • Health Informatics (1563)
  • Health Policy (737)
  • Health Systems and Quality Improvement (605)
  • Hematology (238)
  • HIV/AIDS (506)
  • Infectious Diseases (except HIV/AIDS) (11655)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (239)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2146)
  • Nursing (134)
  • Nutrition (338)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1183)
  • Ophthalmology (365)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (147)
  • Palliative Medicine (50)
  • Pathology (312)
  • Pediatrics (698)
  • Pharmacology and Therapeutics (302)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2187)
  • Public and Global Health (4672)
  • Radiology and Imaging (781)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)